Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

CPIX vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CPIX
Cumberland Pharmaceuticals Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$65M
5Y Perf.+30.7%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$91.09B
5Y Perf.+374.1%

CPIX vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CPIX logoCPIX
MCK logoMCK
IndustryDrug Manufacturers - Specialty & GenericMedical - Distribution
Market Cap$65M$91.09B
Revenue (TTM)$42M$397.96B
Net Income (TTM)$-7M$4.34B
Gross Margin82.9%3.4%
Operating Margin-17.2%1.3%
Forward P/E19.3x
Total Debt$10M$7.39B
Cash & Equiv.$11M$5.69B

CPIX vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CPIX
MCK
StockMay 20May 26Return
Cumberland Pharmace… (CPIX)100130.7+30.7%
McKesson Corporation (MCK)100474.1+374.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: CPIX vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK leads in 5 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Cumberland Pharmaceuticals Inc. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
CPIX
Cumberland Pharmaceuticals Inc.
The Growth Play

CPIX is the clearest fit if your priority is growth exposure.

  • Rev growth 17.6%, EPS growth 58.7%, 3Y rev CAGR 2.0%
  • 17.6% revenue growth vs MCK's 16.2%
  • Better valuation composite
Best for: growth exposure
MCK
McKesson Corporation
The Income Pick

MCK carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 17 yrs, beta 0.04, yield 0.4%
  • 351.9% 10Y total return vs CPIX's -7.0%
  • Lower volatility, beta 0.04, current ratio 0.90x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthCPIX logoCPIX17.6% revenue growth vs MCK's 16.2%
ValueCPIX logoCPIXBetter valuation composite
Quality / MarginsMCK logoMCK1.1% margin vs CPIX's -17.6%
Stability / SafetyMCK logoMCKBeta 0.04 vs CPIX's 1.09
DividendsMCK logoMCK0.4% yield; 17-year raise streak; the other pay no meaningful dividend
Momentum (1Y)MCK logoMCK+5.0% vs CPIX's -0.9%
Efficiency (ROA)MCK logoMCK5.3% ROA vs CPIX's -10.5%, ROIC 5.4% vs -8.6%

CPIX vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CPIXCumberland Pharmaceuticals Inc.
FY 2025
Product
74.8%$40M
Product - Vibativ
17.6%$9M
Product - Other
7.6%$4M
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

CPIX vs MCK — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCKLAGGINGCPIX

Income & Cash Flow (Last 12 Months)

MCK leads this category, winning 4 of 6 comparable metrics.

MCK is the larger business by revenue, generating $398.0B annually — 9488.8x CPIX's $42M. MCK is the more profitable business, keeping 1.1% of every revenue dollar as net income compared to CPIX's -17.6%. On growth, MCK holds the edge at +11.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCPIX logoCPIXCumberland Pharma…MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$42M$398.0B
EBITDAEarnings before interest/tax-$4M$5.8B
Net IncomeAfter-tax profit-$7M$4.3B
Free Cash FlowCash after capex$1M$10.1B
Gross MarginGross profit ÷ Revenue+82.9%+3.4%
Operating MarginEBIT ÷ Revenue-17.2%+1.3%
Net MarginNet income ÷ Revenue-17.6%+1.1%
FCF MarginFCF ÷ Revenue+3.2%+2.5%
Rev. Growth (YoY)Latest quarter vs prior year-22.0%+11.4%
EPS Growth (YoY)Latest quarter vs prior year-3.8%+38.2%
MCK leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — CPIX and MCK each lead in 2 of 4 comparable metrics.

On an enterprise value basis, MCK's 18.5x EV/EBITDA is more attractive than CPIX's 25.7x.

MetricCPIX logoCPIXCumberland Pharma…MCK logoMCKMcKesson Corporat…
Market CapShares × price$65M$91.1B
Enterprise ValueMkt cap + debt − cash$64M$92.8B
Trailing P/EPrice ÷ TTM EPS-23.00x28.91x
Forward P/EPrice ÷ next-FY EPS est.19.28x
PEG RatioP/E ÷ EPS growth rate0.74x
EV / EBITDAEnterprise value multiple25.70x18.53x
Price / SalesMarket cap ÷ Revenue1.47x0.25x
Price / BookPrice ÷ Book value/share2.66x
Price / FCFMarket cap ÷ FCF13.52x17.43x
Evenly matched — CPIX and MCK each lead in 2 of 4 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 4 of 6 comparable metrics.
MetricCPIX logoCPIXCumberland Pharma…MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity-29.7%
ROA (TTM)Return on assets-10.5%+5.3%
ROICReturn on invested capital-8.6%+5.4%
ROCEReturn on capital employed-6.6%+30.5%
Piotroski ScoreFundamental quality 0–966
Debt / EquityFinancial leverage0.41x
Net DebtTotal debt minus cash-$1M$1.7B
Cash & Equiv.Liquid assets$11M$5.7B
Total DebtShort + long-term debt$10M$7.4B
Interest CoverageEBIT ÷ Interest expense-15.15x25.04x
MCK leads this category, winning 4 of 6 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — CPIX and MCK each lead in 3 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $40,840 today (with dividends reinvested), compared to $16,185 for CPIX. Over the past 12 months, MCK leads with a +5.0% total return vs CPIX's -0.9%. The 3-year compound annual growth rate (CAGR) favors CPIX at 37.5% vs MCK's 26.8% — a key indicator of consistent wealth creation.

MetricCPIX logoCPIXCumberland Pharma…MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date+9.8%-9.6%
1-Year ReturnPast 12 months-0.9%+5.0%
3-Year ReturnCumulative with dividends+160.1%+104.0%
5-Year ReturnCumulative with dividends+61.9%+308.4%
10-Year ReturnCumulative with dividends-7.0%+351.9%
CAGR (3Y)Annualised 3-year return+37.5%+26.8%
Evenly matched — CPIX and MCK each lead in 3 of 6 comparable metrics.

Risk & Volatility

MCK leads this category, winning 2 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than CPIX's 1.09 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MCK currently trades 74.4% from its 52-week high vs CPIX's 69.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCPIX logoCPIXCumberland Pharma…MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5001.09x0.04x
52-Week HighHighest price in past year$6.27$999.00
52-Week LowLowest price in past year$1.85$637.00
% of 52W HighCurrent price vs 52-week peak+69.7%+74.4%
RSI (14)Momentum oscillator 0–10075.525.8
Avg Volume (50D)Average daily shares traded1.2M737K
MCK leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

MCK is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.

MetricCPIX logoCPIXCumberland Pharma…MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$1006.50
# AnalystsCovering analysts31
Dividend YieldAnnual dividend ÷ price+0.4%
Dividend StreakConsecutive years of raises17
Dividend / ShareAnnual DPS$2.69
Buyback YieldShare repurchases ÷ mkt cap+0.4%+3.5%
Insufficient data to determine a leader in this category.
Key Takeaway

MCK leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.

Best OverallMcKesson Corporation (MCK)Leads 3 of 6 categories
Loading custom metrics...

CPIX vs MCK: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is CPIX or MCK a better buy right now?

For growth investors, Cumberland Pharmaceuticals Inc.

(CPIX) is the stronger pick with 17. 6% revenue growth year-over-year, versus 16. 2% for McKesson Corporation (MCK). McKesson Corporation (MCK) offers the better valuation at 28. 9x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — CPIX or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +308.

4%, compared to +61. 9% for Cumberland Pharmaceuticals Inc. (CPIX). Over 10 years, the gap is even starker: MCK returned +348. 1% versus CPIX's -8. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — CPIX or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Cumberland Pharmaceuticals Inc. 's 1. 09β — meaning CPIX is approximately 2432% more volatile than MCK relative to the S&P 500.

04

Which is growing faster — CPIX or MCK?

By revenue growth (latest reported year), Cumberland Pharmaceuticals Inc.

(CPIX) is pulling ahead at 17. 6% versus 16. 2% for McKesson Corporation (MCK). On earnings-per-share growth, the picture is similar: Cumberland Pharmaceuticals Inc. grew EPS 58. 7% year-over-year, compared to 14. 9% for McKesson Corporation. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — CPIX or MCK?

McKesson Corporation (MCK) is the more profitable company, earning 0.

9% net margin versus -6. 4% for Cumberland Pharmaceuticals Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus -6. 3% for CPIX. At the gross margin level — before operating expenses — CPIX leads at 85. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — CPIX or MCK?

In this comparison, MCK (0.

4% yield) pays a dividend. CPIX does not pay a meaningful dividend and should not be held primarily for income.

07

Is CPIX or MCK better for a retirement portfolio?

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +348. 1% 10Y return). Both have compounded well over 10 years (MCK: +348. 1%, CPIX: -8. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between CPIX and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

CPIX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 49%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CPIX and MCK on the metrics below

Revenue Growth>
%
(CPIX: -22.0% · MCK: 11.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.